Distinguished in Secondary Immunodeficiency (SID)

Dr. Matthew S. Davids

Hematology Oncology | Oncology
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Secondary Immunodeficiency (SID)
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Davids is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Davids is rated as a Distinguished provider by MediFind in the treatment of Secondary Immunodeficiency (SID). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Davids is currently accepting new patients.

His clinical research consists of co-authoring 218 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Secondary Immunodeficiency (SID).

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Newton-Wellesley Hospital
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide or Pembrolizumab in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.
A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide or Pembrolizumab in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.
Enrollment Status: Recruiting
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drugs: NeoVax, Cyclophosphamide, Pembrolizumab
Study Phase: Phase 1
A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug
Study Drugs: Obinutuzumab, Ibrutinib
Study Phase: Phase 1
A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome
A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: Duvelisib, Venetoclax
Study Phase: Phase 1/Phase 2
Venetoclax Plus Dose-adjusted R-EPOCH or R-CHOP for Richter's Syndrome
Venetoclax Plus Dose-adjusted R-EPOCH or R-CHOP for Richter's Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Other, Drug
Study Drug: Venetoclax
Study Phase: Phase 2
A Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia
A Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug
Study Drugs: Venetoclax, Obinutuzumab, Acalabrutinib
Study Phase: Phase 2
A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination With PD-1 Antagonist Nivolumab in Patients With Transformed Chronic Lymphocytic Leukemia (Richter's Transformation) or Non-Hodgkin Lymphoma
A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination With PD-1 Antagonist Nivolumab in Patients With Transformed Chronic Lymphocytic Leukemia (Richter's Transformation) or Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Drug, Biological
Study Drugs: Copanlisib, Nivolumab
Study Phase: Phase 1
A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Fludarabine, Cyclophosphamide, Rituximab
Study Phase: Phase 2
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drugs: Umbralisib, Ibrutinib
Study Phase: Phase 1
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: November 18, 2023
Intervention Type: Biological, Drug
Study Drugs: Brexucabtagene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
View 9 Less Clinical Trials

218 Total Publications

Triplet Therapies in Chronic Lymphocytic Leukemia.
Triplet Therapies in Chronic Lymphocytic Leukemia.
Journal: Hematology/oncology clinics of North America
Published: July 24, 2025
Similar Doctors
Experienced in Secondary Immunodeficiency (SID)
Dr. Tarek H. Mouhieddine
Hematology Oncology | Hematology | Oncology
Experienced in Secondary Immunodeficiency (SID)
Dr. Tarek H. Mouhieddine
Hematology Oncology | Hematology | Oncology
450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Experience:
9+ years
Languages Spoken:
English
See accepted insurances

Tarek Mouhieddine is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Mouhieddine has been practicing medicine for over 9 years and is rated as a Distinguished provider by MediFind in the treatment of Secondary Immunodeficiency (SID). His top areas of expertise are Smoldering Multiple Myeloma, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Relapsed Refractory Multiple Myeloma (RRMM).

Experienced in Secondary Immunodeficiency (SID)
Dr. Irene S. Ghobrial
Oncology | Hematology
Experienced in Secondary Immunodeficiency (SID)
Dr. Irene S. Ghobrial
Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Irene Ghobrial is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Ghobrial is rated as an Elite provider by MediFind in the treatment of Secondary Immunodeficiency (SID). Her top areas of expertise are Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant. Dr. Ghobrial is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Davids's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 7 Distinguished Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile